跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
HEMOSATE ULTRA HS2125 - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
HEMOSATE ULTRA HS2125
Authorized
STANDARD
HEMOSATE ULTRA HS2125
chief medical supplies ltd
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
f6bfd49a3d33df76
Company
chief medical supplies ltd
Type
Standard
Approval Details
Approval Id
f6bfd49a3d33df76
Drug Approval Canada Name
HEMOSATE ULTRA HS2125
Product Name
HEMOSATE ULTRA HS2125
Status
Marketed
Status Date
2021-01-15
Original Market Date
2020-02-26
Din
02413906
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Haemodialysis
Schedule
Ethical
Ahfs
40:34.00*
Atc Original
B05ZA HEMODIALYTICS, CONCENTRATES
Atc Name
b 05 za
Aig Number
0752576003
Company Name
chief medical supplies ltd
Company Address
411 19th St Se, Calgary, Alberta, Canada, T2E 6J7
Active Ingredients
CALCIUM CHLORIDE
6.24 G / L
CITRIC ACID
6.91 G / L
SODIUM ACETATE
1.11 G / L
SODIUM CHLORIDE
263 G / L
POTASSIUM CHLORIDE
6.71 G / L
DEXTROSE
49.5 G / L
MAGNESIUM CHLORIDE
2.14 G / L
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
f6bfd49a3d33df76
Type
Standard
Back to Health Canada Approvals